Molecules called "chaperones" facilitate correct protein folding.
The analogy is often made comparing proteins with machines. It's an apt analogy, and like a bent or twisted machine, a misshapen protein is unable to function properly. Proteins are long chains of amino acids, folded into a certain configuration that allows them to perform a mechanical function. When they're folded incorrectly, they perform that function poorly or not at all, and that malfunction can lead to disease.
In humans, for example, misfolded proteins lay at the heart of diseases such as phenylketonuria (PKU) and cystic fibrosis. Many of these diseases have genetic origins, and much research has focused on correcting the gene. An alternative approach may be to look for an agent that can restore a protein to its proper shape. This approach might, in theory, also restore the protein's function.
Indeed, in nature, molecules called "chaperones" facilitate correct protein folding. Angel Pey and colleagues at the University of Bergen in Norway, the Universidad de Zaragoza in Spain, the Biocomputation and Complex Systems Physics Institute also in Zaragoza, and the University of Zurich in Switzerland, tested a panel of chemicals to see whether any would act like chaperones and restore the shape and function of the protein phenylalanine hydroxylase (PAH), the protein when misfolded leads to PKU.
In a report in the Journal of Clinical Investigation, the team reports that several chemicals showed evidence of improving activity in animal models. It remains to be seen whether these particular compounds can be developed into drugs. But the larger message for drug developers is that it may be worthwhile to look for drugs with chaperone-like activity when trying to reverse the symptoms of genetically determined diseases.
Source: A.L. Pey et al., "Identification of Pharmacological Chaperones as Potential Therapeutic Agents to Treat Phenylketonuria," Jrnl. of Clin. Invest. 118, 2858–2867 (2008).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.